Inventor · disambiguated record
Michael Brandt
Also filed as: BRANDT MICHAEL · BRANDT MICHAEL R · BRANDT MICHAEL RICHARD
28 granted patents·13 pending applications·351 citations·filing 1994–2025
96Inventor score
Files withROCHE DIAGNOSTICS GMBH10WYETH CORP5Sanofi Biotechnology SAS4HOFFMANN LA ROCHE3ROCHE PALO ALTO LLC3
Top patents by PatentIndex Score
41 records- 0195US11198728B2Monoclonal anti-IL-1RAcp antibodiesSanofi Biotechnology SAS·Filed 2020·Granted Dec 14, 2021·4 cites·22 claims
- 0295US6391633B1Production of erythropoietin by endogenous gene activationROCHE DIAGNOSTICS GMBH·Filed 1998·Granted May 21, 2002·158 cites·22 claims
- 0393US10906971B2Monoclonal anti-IL-1RAcP antibodiesSanofi Biotechnology SAS·Filed 2016·Granted Feb 2, 2021·9 cites·6 claims
- 0489US11091561B2HER-2 binding antibodiesMAB DISCOVERY GMBH·Filed 2017·Granted Aug 17, 2021·4 cites·21 claims
- 0587US12129307B2HER-2 binding antibodiesMAB DISCOVERY GMBH·Filed 2021·Granted Oct 29, 2024·1 cites·18 claims
- 0686US12024564B2Humanized anti-IL-1R3 antibodiesSANOFI BIOTECHNOLOGY·Filed 2021·Granted Jul 2, 2024·1 cites·15 claims
- 0786US6544748B2Preparation of erythropoietin by endogenous gene activationROCHE DIAGNOSTICS GMBH·Filed 2001·Granted Apr 8, 2003·10 cites·33 claims
- 0885US11203642B2Humanized anti-IL-1R3 antibodiesSanofi Biotechnology SAS·Filed 2017·Granted Dec 21, 2021·4 cites·9 claims
- 0984US7214532B2Methods for identifying human cell lines useful for endogenous gene activation, isolated human cell lines identified thereby, and uses thereofROCHE DIAGNOSTICS GMBH·Filed 2003·Granted May 8, 2007·9 cites·5 claims
- 1083US8883975B2Antibodies against IL-18R1 and uses thereofBRANDT MICHAEL·Filed 2011·Granted Nov 11, 2014·14 cites·22 claims
- 1183US7951829B2Benzimidazole modulators of VR1JANSSEN PHARMACEUTICA NV·Filed 2007·Granted May 31, 2011·6 cites·17 claims
- 1283US6790852B22-(2,6-dichlorophenyl)-diarylimidazolesHOFFMANN LA ROCHE·Filed 2003·Granted Sep 14, 2004·19 cites·48 claims
- 1381US7098200B2[[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of painWYETH CORP·Filed 2002·Granted Aug 29, 2006·10 cites·34 claims
- 1478US5610280AMonoclonal antibodies against melanomaBOEHRINGER MANNHEIM GMBH·Filed 1994·Granted Mar 11, 1997·39 cites·8 claims
- 1577US12240898B2Monoclonal anti-IL-1RAcP antibodiesSanofi Biotechnology SAS·Filed 2021·Granted Mar 4, 2025·0 cites·14 claims
- 1677US6555373B1Methods for identifying human cell lines useful for endogenous gene activation isolated human cell lines identified thereby, and uses thereofROCHE DIAGNOSTICS GMBH·Filed 2000·Granted Apr 29, 2003·4 cites·7 claims
- 1777US2024409644A1Humanized anti-il-1r3 antibodiesSANOFI BIOTECHNOLOGY·Filed 2024·Application pending·0 cites
- 1875US7951920B2Conjugate of an antibody against CCR5 and an antifusogenic peptideROCHE PALO ALTO LLC·Filed 2007·Granted May 31, 2011·2 cites·5 claims
- 1975US7214514B2Identification of human cell lines for the production of human proteins by endogenous gene activationROCHE DIAGNOSTICS GMBH·Filed 2004·Granted May 8, 2007·3 cites·13 claims
- 2075US6846673B2Identification of human cell lines for the production of human proteins by endogenous gene activationROCHE DIAGNOSTICS GMBH·Filed 2002·Granted Jan 25, 2005·5 cites·11 claims
- 2172US2025154245A1Monoclonal anti-il-1racp antibodiesSANOFI BIOTECHNOLOGY·Filed 2025·Application pending·0 cites
- 2271US7186529B2Preparation of erythropoietin by endogenous gene activationROCHE DIAGNOSTICS GMBH·Filed 2003·Granted Mar 6, 2007·2 cites·26 claims
- 2370US5888813AMonoclonal antibodies against human pancreatic islet cellsBOEHRINGER MANNHEIM GMBH·Filed 1995·Granted Mar 30, 1999·19 cites·8 claims
- 2469US7615216B2Antibodies against CCR5 and uses thereofROCHE PALO ALTO LLC·Filed 2006·Granted Nov 10, 2009·1 cites·7 claims
- 2565US6946471B22-(2,6-Dichlorophenyl)-DiarylimidazolesHOFFMANN LA ROCHE·Filed 2004·Granted Sep 20, 2005·2 cites·16 claims
- 2663US7759346B2[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of painWYETH LLC·Filed 2006·Granted Jul 20, 2010·0 cites·6 claims
- 2760US6214568B1Monoclonal antibodies of isotype IgG which bind specifically to glutamate decarboxylase, and uses thereofROCHE DIAGNOSTICS GMBH·Filed 1998·Granted Apr 10, 2001·10 cites·8 claims
- 2855US6395484B1Identification of human cell lines for the production of human proteins by endogenous gene activationROCHE DIAGNOSTICS GMBH·Filed 1998·Granted May 28, 2002·9 cites·9 claims
- 2954US6548296B1Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereofROCHE DIAGNOSTICS GMBH·Filed 1998·Granted Apr 15, 2003·6 cites·15 claims
- 3050US7846896B2PEG conjugates of NK4HOFFMANN LA ROCHE·Filed 2007·Granted Dec 7, 2010·0 cites·7 claims
- 3146US2011190364A1Benzimidazole modulators of vr1PLAYER MARK R·Filed 2011·Application pending·0 cites
- 3246US2004110685A1Scatter factor/hepatocyte growth factor antagonist NK4 for the treatment of gliomaFiled 2003·Application pending·0 cites
- 3346US2011190344A1Benzimidazole modulators of vr1PLAYER MARK R·Filed 2011·Application pending·0 cites
- 3446US2005004079A1Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereofWYETH CORP·Filed 2004·Application pending·0 cites
- 3545US2009226434A1Afucosylated antibodies against CCR5 and their use for the treatment of inflammatory conditionsROCHE PALO ALTO LLC·Filed 2009·Application pending·0 cites
- 3645US2005142192A1Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivativesWYETH CORP·Filed 2004·Application pending·0 cites
- 3745US2003024001A1Knock in transgenic mammal containing a non-functional N-terminus of Kv beta 1.1 subunitWYETH CORP·Filed 2002·Application pending·0 cites
- 3844US2006258713A1Treatment of painWYETH CORP·Filed 2006·Application pending·0 cites
- 3944US2003012775A1PEG conjugates of NK4Filed 2002·Application pending·0 cites
- 4042US2009110686A1Antibodies against CCR5 and uses thereofAUER JOHANNES·Filed 2007·Application pending·0 cites
- 4140US2011165182A1Conjugate of an antibody against ccr5 and an antifusogenic peptideBRANDT MICHAEL·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →